Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Equity Income (2021 - 2023)

Intellia Therapeutics has reported Equity Income over the past 3 years, most recently at -$4.7 million for Q4 2023.

  • Quarterly Equity Income fell 45.57% to -$4.7 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$4.7 million through Sep 2024, up 66.59% year-over-year, with the annual reading at -$15.6 million for FY2023, 41.1% down from the prior year.
  • Equity Income was -$4.7 million for Q4 2023 at Intellia Therapeutics, down from -$3.9 million in the prior quarter.
  • Over five years, Equity Income peaked at -$1.3 million in Q4 2021 and troughed at -$4.7 million in Q4 2023.
  • The 3-year median for Equity Income is -$3.2 million (2022), against an average of -$3.1 million.
  • Year-over-year, Equity Income plummeted 145.13% in 2022 and then dropped 11.04% in 2023.
  • A 3-year view of Equity Income shows it stood at -$1.3 million in 2021, then plummeted by 145.13% to -$3.2 million in 2022, then plummeted by 45.57% to -$4.7 million in 2023.
  • Per Business Quant, the three most recent readings for NTLA's Equity Income are -$4.7 million (Q4 2023), -$3.9 million (Q3 2023), and -$4.0 million (Q2 2023).